US 10,071,148 B2 · Immunotherapy against several tumors, such as lung cancer, including NSCLC

Abstract

The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to more than 70 novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

Claims16

Dependent claims

A method of eliciting an immune response in a patient who has non-small cell lung cancer, comprising administering to the patient a population of activated T cells that selectively recognize cancer cells that present a peptide consisting of the amino acid sequence of TLSSIKVEV (SEQ ID NO:

5),
wherein the activated T cells are produced by contacting T cells with an antigen presenting cell that expresses the peptide in a complex with a human class I or II MHC molecule on the surface of the antigen presenting cell for a period of time sufficient to activate the T cells.

Dependencies are inferred from the claim text.

Facts

Application

15/357,838Filed 21 Nov 2016 · continuation

Priority

GB 1313987.85 Aug 2013

Published

US 2017/0202937 A120 Jul 2017

Granted

11 Sep 2018

Term ends

Not estimatedThe source records don’t support an estimate.

Classification21 codes

C07K 7/06
Linear peptides containing only normal peptide links: having 5 to 11 amino acids
A61K 35/17
Blood; Artificial blood: lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
A61K 38/1709
From vertebrates: from mammals
A61K 39/0011
Vertebrate antigens: cancer antigens

Family

Application61/862,213Us provisional application · filed 5 Aug 2013

PCT/EP2014/066755Parent of this continuation · filed 4 Aug 2014

US 2017/0202937 A1Pre-grant publication · published 20 Jul 2017

Application14/908,078Parent of this continuation

US 2016/0168200 A1Published application

US 10,071,148 B2This patent

From the US filing history. Foreign family members aren’t listed.

Immunotherapy against several tumors, such as lung cancer, including NSCLC

Life of this patent

Immunotherapy against several tumors, such as lung cancer, including NSCLC

Life of this patent

Abstract

Claims16